Plain-English translation of NCT07914556 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new medication called in adults with three types of blood cancers: acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and multiple myeloma (MM). The trial has two parts: the first part finds the safest dose of the medication, and the second part tests whether that dose actually works to treat these cancers. Researchers will also monitor your body's immune response and how the medication moves through your system.
These three blood cancers are difficult to treat, especially when they come back or stop responding to standard therapies. This trial exists to see if this new treatment approach might offer hope for patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
In Part 1, you would receive gradually increasing doses of the medication to help researchers find the safest dose level. In Part 2, you would receive the medication at the dose determined to be safe in Part 1. Throughout the trial, you will have regular clinic visits for blood tests, physical exams, and scans to monitor how you are responding and whether you experience any side effects. The exact length and frequency of visits will depend on which part of the trial you join and your individual response to the treatment.
AI-generated summary from trial data · Nov 3, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Enrollment target
~122 participants
Started
September 2026
Primary completion
December 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jiangjiang Lv
Mabwell (Shanghai) Bioscience Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.